Moleculin Biotech, Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter report. The company is a clinical-stage oncology drug developer with no approved products and no product sales revenue.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11.013 million | $9.728 million |
| General and administrative expense | $6.312 million | $5.229 million |
| Total operating expenses / operating loss | $17.524 million | $15.025 million |
| Net loss | $13.205 million | $11.876 million |
| Net loss per share, basic and diluted | $0.32 | $0.46 |
| Cash used in operating activities | $17.198 million | $12.203 million |
| Cash and cash equivalents at year-end | $10.735 million | $7.134 million |
There were no product revenues, so operating margins are not meaningful. The 2019 net loss included a $4.062 million noncash gain from revaluing warrant liabilities; operating loss more directly reflects operating costs. The company reported $1.537 million of stock-based compensation.
At December 31, 2019, current assets were $13.484 million and current liabilities were $3.570 million. Total liabilities were $9.664 million, including a $5.818 million warrant liability and $0.379 million of operating lease liabilities. The balance sheet does not list conventional borrowing debt. Accumulated deficit was $39.561 million. The company reported a $0.229 million income tax benefit, primarily associated with research and development tax credits.
Financing activities provided $20.854 million in 2019, primarily from common-stock sales and warrant exercises. The company raised approximately $6.0 million gross in a February 2020 stock-and-warrant offering. Management estimated available resources would fund planned operations into, but not beyond, the near term—toward the end of the third quarter of 2020—and disclosed substantial doubt about its ability to continue as a going concern without additional financing.
Material changes versus 2018
- R&D expense increased about 13%, mainly reflecting more clinical trials, drug manufacturing, and development activity.
- G&A expense increased about 21%, primarily from added personnel and stock-based compensation.
- Operating cash use rose by approximately $5.0 million as clinical and preclinical activity expanded.
- Net loss increased by approximately $1.3 million, despite a larger warrant revaluation gain. Loss per share declined from $0.46 to $0.32, while weighted-average shares increased from 25.9 million to 40.7 million.
- Year-end common shares outstanding increased from 28.5 million to 45.7 million. The February 2020 financing added shares and warrants; 53.2 million common shares were outstanding as of March 10, 2020.
Business, outlook, and key risks
- Pipeline: Annamycin was being tested for relapsed or refractory acute myeloid leukemia (AML) in US and Polish Phase 1/2 studies. WP1066 was in a physician-sponsored Phase 1 brain-tumor trial; WP1220 completed a small Polish Phase 1 proof-of-concept study for cutaneous T-cell lymphoma (CTCL). Additional programs remained preclinical.
- Clinical updates disclosed after year-end: The US Annamycin Phase 1 portion met its safety objective at tested doses. The company reported no observed cardiotoxicity among treated patients and preliminary response signals, but emphasized the small patient population and early-stage nature of the data. The ongoing European study was dose-escalating. These findings do not establish efficacy or assure approval.
- WP1220: In five enrolled subjects, four improved on assessed lesions; the company reported a median 56% improvement in the CAILS score. It planned discussions with regulators about a Phase 2 study. Results from this small study require confirmation.
- Management plans: The company intended to establish a recommended Phase 2 dose for Annamycin in Europe and seek FDA and EMA agreement on a potential single-arm pivotal Phase 2 trial and accelerated-approval approach. Regulatory acceptance is not assured. It also planned a US Annamycin trial in lung metastases and anticipated additional trials and development work.
- Funding and dilution: Management said it would continue to need external capital. Funding avenues included equity offerings, a $20 million Lincoln Park facility (of which $2.8 million had been used by year-end) and a $15 million ATM facility, under which no shares had been sold as of the filing. Equity financing and outstanding warrants could materially dilute shareholders.
- COVID-19 and operations: The company sourced Annamycin production in Italy and conducted trials in Poland. At filing, it reported no drug-supply interruption but noted restricted clinic access for monitoring and substantial uncertainty about further disruption.
- Other notable risks: The company relied on third parties for manufacturing, research, and clinical-trial operations; had no commercial infrastructure; and disclosed that Annamycin’s original composition-of-matter patent protection had expired, with new patent applications still pending. Related-party sublicenses with entities affiliated with founder Dr. Waldemar Priebe merit review.
- Governance and listing: Management concluded internal control over financial reporting was ineffective because of a material weakness in segregation of duties, while describing remediation efforts. The filing also reported Nasdaq bid-price noncompliance after the share price remained below $1 for 30 consecutive business days by March 18, 2020.
Most important facts for investors to verify
- Current cash runway, subsequent cash burn, and whether additional financing has been secured on acceptable terms.
- Clinical-trial enrollment, safety, response data, and regulatory feedback for Annamycin and WP1220; distinguish company-reported preliminary findings from confirmed clinical benefit.
- Whether COVID-related restrictions or manufacturing issues affected trial monitoring, enrollment, or drug supply.
- Potential dilution from the February 2020 offering, outstanding warrants and options, and remaining Lincoln Park or ATM capacity.
- Progress in remediating the internal-control material weakness, and the status of Nasdaq listing compliance.
- Terms and performance of related-party licensing arrangements, including WPD’s development-funding commitments.